Getinge, a competitor in the medical technology sector, announced its plans to phase out its surgical perfusion business. This strategic decision by Getinge aims to re-allocate resources and focus on other areas with higher growth potential, specifically the ECMO market.
This exit from the surgical perfusion market by a significant competitor is expected to open doors for other players, including LivaNova. LivaNova's Cardiopulmonary segment, which includes heart-lung machines and oxygenators, is well-positioned to potentially gain market share.
LivaNova's Essenz Perfusion System and its comprehensive suite of cardiopulmonary solutions could benefit from reduced competition in this segment. The company has been investing in manufacturing capacity and product upgrades, which could enable it to capitalize on this market shift and drive further growth.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.